Clinical Trial Working Groups
|
 |
- Approved LOI:
- ER+ and/or PR+ and HER2- breast cancer (Illinois)
- AR+ triple negative breast cancer (Wisconsin)
-
Current concepts:
- First line triple negative metastatic breast cancer (Penn State)
- Newly diagnosed ER+, HER2- breast cancer (Minnesota)
- Triple negative breast cancer (Wisconsin)
- Next call: Wednesday, February 3 at 4 p.m. ET / 3 p.m. CT
- Trial in start-up: Endometrial carcinoma (Northwestern)
- Current concept: Ovarian (Rutgers)
- Next call: Thursday, March 3 at 2 p.m. ET / 1 p.m. CT.
- Current concepts:
- Squamous cell carcinoma of the skin (Rutgers)
- Melanoma brain metastasis (Michigan)
- Uveal melanoma (Michigan)
- Next call: TBD.
- Current concept: Lymphoma/multiple myeloma (Indiana) - see also lymphoma
- Next call: Friday, March 4 at 10 a.m. ET / 9 a.m. CT.
- Current concepts:
- AML (Illinois)
- AML (Indiana)
- MDS (Penn State)
- Next call: Thursday, March 31 at 3 p.m. ET / 2 p.m. CT
- Approved LOI:
- Esophageal (Indiana) - see also gastrointestinal
- NSCLC (Illinois)
- Current concepts:
- Splice variants in lung cancer in women (Illinois)
- HER2 expression and targeted therapy (Illinois)
- Small cell lung cancer (Illinois) - 2 concepts
- NSCLC (Indiana)
- Next call: Friday, March 11 at 1 p.m. ET / 12 p.m. CT
To Discuss Protocols: Contact Jessica Roy at
[email protected] or 317-634-5842, ext. 19
To Join a CTWG or Submit an LOI: Contact Donna LaPlaca Sullivan at
[email protected] or 317-634-5842, ext. 40.
|
|
|
|
|
Investigators present Phase Ib results of BTCRC-GU14-003
|
Investigators within the Big Ten Cancer Research Consortium recently presented results from the Phase Ib portion of the BTCRC-GU14-003 study, establishing the maximum tolerated dose of pembrolizumab and bevacizumab in combination for subjects with metastatic clear cell renal carcinoma after failure of at least one systemic therapy for metastatic disease.
In a poster session presented at the 2016 Genitourinary Cancers Symposium in San Francisco in January, investigators reported no dose-limiting toxicities or serious adverse events related to the study drug had been reported. The 200 mg fixed dose of pembrolizumab and 15 mg/kg dose of bevacizumab, both given every three weeks, was determined to be safe and recommended for a multicenter Phase 2 study that is ongoing.
Authors of the study include Arkadiusz Z. Dudek, MD, PhD, University of Illinois at Chicago; R. Alejandro Sica, MD, University of Illinois at Chicago; Amer Sidani, MD, University of Illinois at Chicago; Gautam Gopalji Jha, MD, University of Minnesota; Hui Xie, PhD, University of Illinois at Chicago; Ajjai Shivaram Alva, MD, University of Michigan; Mark N. Stein, MD, Rutgers Cancer Institute of New Jersey; and Eric A. Singer, MD, MA, FACS, Rutgers Cancer Institute of New Jersey.
|
|
Michigan State University Breslin Cancer Center
"In his recent State of the Union address, President Obama called for a 'moonshot' to cure cancer. With our partners in the Big Ten Cancer Research Consortium, we expect to play a major role in reaching that goal."
Read more in this conversation
with Anas Al-Janadi, MD, medical director of the Michigan State University Breslin Cancer Center, our featured member for February.
|
|
University of Illinois Cancer Center
"As part of the consortium, we carry the University of Illinois name through highly responsive networking to all of the other institutions. We are introduced to and have a relationship with clinicians and researchers from this pipeline of outstanding schools, who share similar research goals. Not only do we support each other as scientists and as clinicians, but we support the research itself, and having this network provides for a framework and foundation to build ideas and test hypotheses."
Read more in this conversation
with Arkadiusz Dudek, MD, PhD, professor of medicine, hematology/oncology, at the University of Illinois College of Medicine, our featured member for January.
To see past member features, click here. |
|
Q&A: Correlative Research
|
Our BTCRC FAQ series continues with common questions related to
correlative research. Questions addressed in this FAQ include:
- In what aspects of a clinical trial are correlative research managers at BTCRC Administrative Headquarters able to assist?
- Why am I provided a Study Procedures Manual along with the protocol?
- Why am I instructed to use only the correlative specimen collection kits provided by the BTCRC Administrative Headquarters instead of supplies at my site?
- Why is it important to enter accurate biospecimen data into the EDC system in a timely manner?
|
As 2015 wound down, Big Ten university researchers kept their momentum going. The past year yielded many accomplishments worthy of celebration.
Read more
.
|
|
Making gains against cervical cancer
According to the National Cancer Institute, an estimated 12,900 new cases of cervical cancer occurred in the United States in 2015. The disease also caused an estimated 4,100 deaths. But the dawn of 2016 ushers in exciting opportunities for a new year of progress in cancer research, prevention, and treatment. January was National Cervical Cancer Awareness Month, and member institutions of the Big Ten Cancer Research Consortium are leading the fight against this highly preventable, highly treatable cancer. Read more.
|
|
NCI-designated centers issue joint HPV statement
All 69 National Cancer Institute (NCI)-designated cancer centers, including nine members of the Big Ten Cancer Research Consortium, have issued a joint statement urging HPV vaccination for the prevention of cancer. Several types of high-risk HPV are responsible for the vast majority of cervical, anal, oropharyngeal (middle throat) and other genital cancers. While many of these cancers are preventable through the HPV vaccine, vaccination rates across the U.S. remain low.
Read more.
|
|
|
